انتقل إلى المحتوى الرئيسي
الترجمة جارية — يُعرض هذا المحتوى باللغة الإنجليزية أثناء إعداد نسختك بلغتك.
العودة إلى النقاشات

الرئيس التنفيذي لشركة نوفارتس فاسانت ناراسيمهان حول تحويل شركة عمرها 250 سنة

Business
عالمي
بدأ في February 17, 2026

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including ...

مقالات المصادر

إضافة تصريح التحليل 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 تصريحات للتصويت • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM نشر بواسطة will • Feb 17, 2026
Partnerships with startups should focus on long-term collaboration, as short-term gains may lead to unsustainable practices in the biotech industry.

الترجمة قيد الإعداد

Vote options for this statement: agree, disagree, or unsure
💬 عرض النقاش
Be first to respond
Vote to see results
CLAIM نشر بواسطة will • Feb 17, 2026
AI's role in drug discovery at Novartis could streamline research processes, but ethical concerns about data use must be addressed.

الترجمة قيد الإعداد

Vote options for this statement: agree, disagree, or unsure
💬 عرض النقاش
Be first to respond
Vote to see results
CLAIM نشر بواسطة will • Feb 17, 2026
The focus on high-value therapies may neglect affordable treatments, widening the gap in healthcare access for underserved populations.

الترجمة قيد الإعداد

Vote options for this statement: agree, disagree, or unsure
💬 عرض النقاش
Be first to respond
Vote to see results
CLAIM نشر بواسطة will • Feb 17, 2026
Emphasizing cell and gene therapies positions Novartis as a leader in biotech, essential for competing against rising players like China.

الترجمة قيد الإعداد

Vote options for this statement: agree, disagree, or unsure
💬 عرض النقاش
Be first to respond
Vote to see results
CLAIM نشر بواسطة will • Feb 17, 2026
Transforming Novartis into a pure play medicines company will drive innovation and significantly enhance patient care worldwide.

الترجمة قيد الإعداد

Vote options for this statement: agree, disagree, or unsure
💬 عرض النقاش
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us